AOD

$70.00
AOD9604 is a modified peptide fragment of human growth hormone (hGH 176–191) containing a disulfide bridge. Initially developed as a fat-burning agent, it promotes lipolysis and inhibits lipogenesis in animal studies. Beyond weight management, AOD9604 has also shown potential benefits in cardiovascular health, cartilage repair, and metabolic syndrome. Its non-growth-promoting nature makes it a unique candidate for obesity-related therapies.
Select options
Quick view

Cagrilintide

$100.00
Cagrilintide is a long-acting analogue of amylin, a peptide co-secreted with insulin. It has shown potential in preclinical studies for the treatment of obesity and type 2 diabetes. Beyond metabolic regulation, it is also being investigated for possible roles in liver disease, cardiovascular conditions, and even neurodegenerative disorders like Alzheimer’s, though data in these areas remain limited. Notably, Cagrilintide is often studied in combination with semaglutide, where the two compounds appear to act synergistically to enhance and sustain weight loss. While early results are promising, further clinical trials are needed to confirm safety and efficacy in humans.
Select options
Quick view

IGF LR3

$80.00
IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is a synthetic variant of IGF-1 with an extended half-life—up to 120 times longer than natural IGF-1—due to its reduced affinity for IGF binding proteins. This prolongs its biological activity, making it a powerful agent for promoting muscle growth, enhancing recovery, and supporting fat metabolism. IGF-1 LR3 stimulates cell proliferation and tissue regeneration, and may inhibit myostatin, a negative regulator of muscle growth. Emerging research also points to potential benefits in areas like lactation support, though further studies are needed.
Select options
Quick view

Mazdutide

$140.00
Mazdutide is a dual GLP-1 and glucagon receptor agonist developed to address obesity and metabolic disorders. By simultaneously activating GLP-1 and glucagon pathways, it enhances insulin secretion, suppresses appetite, increases energy expenditure, and promotes fat oxidation. This dual mechanism offers greater weight loss potential compared to traditional GLP-1 agonists. Early clinical trials have shown encouraging results in reducing body weight and improving metabolic parameters, though further studies are ongoing to establish its long-term efficacy and safety.
Select options
Quick view

MOTS-C

$35.00
MOTS-c is a 16-amino acid mitochondrial-derived peptide (MDP) that plays a key role in metabolic regulation. Produced in the mitochondria, it enhances insulin sensitivity, supports glucose metabolism, and helps the body respond to metabolic stress. MOTS-c can translocate to the nucleus to regulate genes involved in energy balance and mitochondrial function. Research suggests it may improve exercise capacity, reduce obesity and insulin resistance, and offer protective effects against conditions like osteoporosis and age-related metabolic disorders. Its potential in promoting metabolic health and longevity makes it a promising target in aging and chronic disease research.
Select options
Quick view

Retatrutide

$100.00
Retatrutide is a novel GGG tri-agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. By activating the glucagon receptor in addition to GLP-1 and GIP pathways, it promotes fat and glycogen breakdown, thereby boosting basal metabolic rate and supporting sustained fat loss. Its effects on appetite suppression and delayed gastric emptying further enhance weight management. Compared to earlier GLP-1 agonists, Retatrutide offers a more comprehensive metabolic approach. Ongoing research continues to explore its full therapeutic potential.
Select options
Quick view

Semaglutide

$50.00
Semaglutide is a long-acting analogue of GLP-1, a naturally occurring peptide that helps regulate blood sugar by stimulating insulin secretion and suppressing glucagon in a glucose-dependent manner. In addition to its role in managing type 2 diabetes, semaglutide has shown benefits in reducing appetite, delaying gastric emptying, and promoting weight loss. Emerging studies also suggest potential protective effects on the heart, liver, and lungs, as well as possible neuroprotective properties relevant to Alzheimer’s disease. Its broad metabolic and systemic actions make it a key candidate in ongoing obesity and chronic disease research.
Select options
Quick view

Survodutide

$120.00
Survodutide is a dual agonist of GLP-1 and glucagon receptors, developed by Boehringer Ingelheim in collaboration with Zealand Pharma. It is being studied for the treatment of obesity and non-alcoholic steatohepatitis (NASH). By combining GLP-1–mediated appetite suppression with glucagon-induced energy expenditure and fat metabolism, survodutide has shown promising effects on weight reduction and liver fat reduction. In clinical trials, survodutide significantly reduced body weight and improved markers of liver health, making it a potential candidate for treating both obesity and metabolic liver disease. Ongoing phase 2 studies aim to confirm its long-term efficacy and safety.
Select options
Quick view

Tirzepatide

$55.00
Tirzepatide is a synthetic dual agonist that targets both the GIP and GLP-1 receptors. This unique mechanism allows it to lower blood glucose levels, improve insulin sensitivity, and significantly enhance satiety, leading to reduced food intake. Initially developed for the treatment of type 2 diabetes, Tirzepatide has also shown promising results in promoting weight loss and offering cardiovascular protection. Its dual action makes it a novel and powerful candidate in the management of metabolic disorders.
Select options
Quick view